Sign In
Buy KTTA
$0.638
-0.0068 (-1.05%)
At Close: Jun 03, 2026
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
07:02am, Tuesday, 02'nd Jun 2026
MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
07:01am, Monday, 04'th May 2026
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation m
MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Monday
01:36am, Monday, 16'th Mar 2026
Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) is projected to announce its results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.18) p
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
05:17am, Friday, 27'th Feb 2026
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:01am, Tuesday, 17'th Feb 2026
Pasithea Therapeutics (Nasdaq: KTTA) will present to Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 25, 2026, 4:00 PM ET
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
07:01am, Tuesday, 13'th Jan 2026
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
07:00am, Tuesday, 02'nd Dec 2025
MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-gene
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
09:20am, Friday, 28'th Nov 2025
Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron
-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomark
-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin rat
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 29.6% – Should You Sell?
02:15am, Saturday, 22'nd Nov 2025
Pasithea Therapeutics Corp. (NASDAQ: KTTA - Get Free Report)'s stock price was down 29.6% during trading on Friday. The stock traded as low as $0.2810 and last traded at $0.2923. Approximately 3,259,5
-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, wit
In new data, MEK inhibitor PAS-004 shows monotherapy partial response, favorable PK and safety profile, supporting best-in-class potential for NF1-PN.
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
